The Comparative Cost-Effectiveness of Cabozantinib, Everolimus and Axitinib in Advanced Renal Cell Carcinoma (ARCC) After Failure of Prior Therapy- Scottish Perspective
Abstract
Authors
J Lister A Vataire B Amzal J Dinet J Meng H Karcher S Gabriel